TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25296247
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug failure
Study: 21959802
Drug: PVP K90
Normalized name: PVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP K90 160 mg/tablet
Study: 16541114
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg oral daily tamsulosin (group 1, n=59)
Study: 14506138
Drug: Two-weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-weekly schedule of gemcitabine (1500 mg/m²) and cisplatin (90 mg/m²)
Study: 14506138
Drug: Weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly schedule of gemcitabine and cisplatin
Study: 14506138
Drug: Two-weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-weekly schedule
Study: 14506138
Drug: Weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly schedule
Study: 8850048
Drug: Topical formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulations containing clobetasol propionate, doxepin hydrochloride, metronidazole, mupirocin, oxiconazole nitrate, and terbinafine hydrochloride
Study: 8850048
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride cream vehicle
Study: 1626168
Drug: Dolotren (D)
Normalized name: Dolorex Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolotren (D) 100 mg, administered b.i.d. for 15 days
Study: 1626168
Drug: Dolotren Retard
Normalized name: Dolorex Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolotren Retard (DR) 100 mg, administered once a day for 15 days
Study: 7416612
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered epinephrine
Study: 7416612
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered aminophylline
Study: 31962198
Drug: Whole breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole breast irradiation (WBI) after endocrine therapy (ET)
Study: 31962198
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) alone (observation)
Study: 20602715
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily (QD) and increased to 120 mg QD at week 7 if < 30% pain reduction
Study: 16829208
Drug: Angiogenesis inhibitor
Normalized name: Angiogenesis inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiogenesis inhibitor
Study: 11707042
Drug: Single stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single stage head‐up tilt table test (HUT) with infusion of 3.44 microg/kg per hour of nitroglycerin
Study: 11707042
Drug: Conventional multistage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional multistage test with infusion of nitroglycerin from 1.72 microg/kg per hour to 5.16 microg/kg per hour
Study: 9597560
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day testosterone transdermal patch (T)
Study: 9597560
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day testosterone transdermal patches (R)
Study: 18713887
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of ketoprofen 1 mg/kg and fentanyl 1 microg/kg
Study: 18713887
Drug: Baseline measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measurements before premedication with midazolam 0.1 mg/kg IV
Study: 10890862
Drug: Topical lodoxamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lodoxamide ophthalmic solution 0.1% (LOS)
Study: 10890862
Drug: Topical cromolyn
Normalized name: cromolyn Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cromolyn sodium ophthalmic solution 4% (CSO)
Study: 2996906
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline
Study: 2996906
Drug: 12 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 micrograms/ml pentoxifylline
Study: 28611006
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg daily for one year
Study: 28611006
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg daily for one year
Study: 22000794
Drug: Pharyngeal anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharyngeal anesthesia with 4 squirts of lidocaine spray
Study: 16563920
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) fenoldopam
Study: 16563920
Drug: Intrarenal (IR)
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarenal (IR) fenoldopam (2 hours after drug discontinuation)
Study: 12062615
Drug: Two fractions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two fractions of high-dose-rate brachytherapy (9 Gy per application, 1 week apart)
Study: 12062615
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy (cisplatin 20 mg/m(2)/day for 5 days during EBRT)
Study: 12062615
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose to rectum from high-dose-rate brachytherapy
Study: 12062615
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose to bladder from high-dose-rate brachytherapy
Study: 2253662
Drug: Ibopamine 400
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 400 mg t.d.s. for 5 to 10 days
Study: 483202
Drug: Bromocriptine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 15 mg/day
Study: 483202
Drug: Full medical
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full medical treatment
Study: 30043207
Drug: PEG-rhG-CSF 100
Normalized name: PEG-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF 100 µg/kg, single subcutaneous injection 72 hours after chemotherapy
Study: 30043207
Drug: rhG-CSF 5
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF 5 µg/kg/day, subcutaneous injection once a day for 14 days or until ANC ≥ 10.0 × 10^9/l twice, starting 72 hours after chemotherapy
Study: 17409825
Drug: Paclitaxel (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (15 mg/m/day)
Study: 17409825
Drug: Paclitaxel (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (6.5 mg/m/day)
Study: 17409825
Drug: Paclitaxel (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (17 mg/m/day)
Study: 17409825
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of paclitaxel with concurrent radiation therapy (RT)
Study: 14635510
Drug: Bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 300 mg/day and nicotine patches
Study: 10516865
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil in the late in-hospital phase of AMI without heart failure
Study: 10516865
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil in the late in-hospital phase of AMI with heart failure
Study: 10516865
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil combined with thrombolysis
Study: 10516865
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil in the early phase of AMI
Study: 1655136
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fraxiparine) 41 IU/kg/day for three days, then 62 IU/kg/day from day 4 to day 10
Study: 1655136
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin at intervals of eight hours, doses adjusted to maintain activated thromboplastin time at two to five seconds above control values
Study: 6128021
Drug: Timolol (0.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (0.5-20 mg)
Study: 6128021
Drug: Timolol (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (27 ng/ml plasma concentration)
Study: 30852479
Drug: Conventional anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticancer drugs
Study: 26587993
Drug: Acetazolamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (up to 4 g/d)
Study: 24583571
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg of hypertonic saline (HTS) over 1 hour
Study: 24583571
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg of hypertonic saline (HTS)
Study: 15903129
Drug: Paroxetine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine pretreatment (20 mg daily for 3 consecutive days)
Study: 15903129
Drug: Paroxetine/tramadol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine/tramadol combination
Study: 15903129
Drug: Paroxetine in
Normalized name: Product containing paroxetine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine in combination with placebo
Study: 10485389
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test for wheat
Study: 8799415
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (mitomycin C and doxorubicin)
Study: 8799415
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific anti-cancer treatment
Study: 1633433
Drug: Phosphatidylserine (Fidia,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (Fidia, 300 mg/d)
Study: 6337787
Drug: Oral verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil, 240 mg
Study: 6337787
Drug: Digoxin, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin, 0.25 mg and 0.5 mg daily
Study: 6337787
Drug: Digoxin, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin, 0.25 mg and verapamil
Study: 30278529
Drug: Yufeining (YFN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yufeining (YFN) treatment
Study: 22205316
Drug: Oral assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral assessment of size and shape
Study: 20478383
Drug: Quercetin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 1000 mg/day for 12 weeks
Study: 18034195
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (short exposure, high-energy laser settings): exposure 0.02 s, 300 microm
Study: 18034195
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (conventional settings): exposure time 0.1 s, power sufficient to produce visible grey-white burns, spot size 300 microm
Study: 12356202
Drug: Nottingham Extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nottingham Extended Activities of Daily Living Scale (EADL)
Study: 3162737
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment focusing on critical features of tooth anatomy and preparation methods
Study: 3162737
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with conventional written and oral descriptions
Study: 27167219
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks ribavirin mono-therapy prior to adding pegIFN-α
Study: 27167219
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks ribavirin double dosing concomitant with pegIFN-α
Study: 27167219
Drug: standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α
Study: 22660371
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (arm restriction)
Study: 20156473
Drug: Perceptual learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptual learning training (repeated measurements of visual-span profiles at 10 degrees below fixation, in four daily sessions)
Study: 12427412
Drug: Isolated lower-limb
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated lower-limb training (3 months of low-level bicycle and treadmill exercise, minute ventilation <25 l/min)
Study: 8649684
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg vasopressin diluted with 20 mL saline
Study: 6360739
Drug: Tromantadine hydrochloride
Normalized name: Tromantadine hydrochloride
DrugBank: Tromantadine (DB13288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tromantadine hydrochloride (TH) ointment
Study: 27931259
Drug: Extracorporeal veno-venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal veno-venous hemoperfusion therapy with the LPS Adsorber
Study: 27931259
Drug: Veno-venous hemoperfusion
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veno-venous hemoperfusion therapy with a placebo adsorber (without active LPS-binding peptide)
Study: 25155070
Drug: Time- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time- and dose-consistent PMI focused on general health (comparison condition)
Study: 21896539
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m² twice daily for 24 weeks)
Study: 17885017
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + folate supplements during pregnancy
Study: 12116053
Drug: Epinephrine 2.5
Normalized name: epinephrine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 2.5 mg sublingual tablet
Study: 12116053
Drug: Epinephrine 10
Normalized name: epinephrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 10 mg sublingual tablet
Study: 12116053
Drug: Epinephrine 0.03
Normalized name: epinephrine 0.032 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.03 mg IM injection (positive control)
Study: 12116053
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl IM injection (negative control)
Study: 9715843
Drug: ddI (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddI (200 mg every 12 hours) alone for 4 days
Study: 9715843
Drug: ritonavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritonavir (600 mg every 12 hours) alone for 4 days
Study: 9715843
Drug: ddI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddI with ritonavir under dose-staggering conditions for 4 days
Study: 8785890
Drug: PUVA combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA combined with topical corticosteroids
Study: 8785890
Drug: PUVA combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA combined with calcipotriene ointment
Study: 7364841
Drug: Negative pi
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative pi meson (pion) radiotherapy at a dose of at least 2700 peak pion rads, delivered at a rate of 100 to 125 rads daily.
Study: 7364841
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation treatment (control group).
Study: 26556603
Drug: SRT2104 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (three escalating doses)
Study: 25193004
Drug: DBT-PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT-PTSD treatment
Study: 25193004
Drug: Treatment-as-usual wait-list
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual wait-list
Study: 17257370
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment (early start)
Study: 15122959
Drug: Voucher‐based reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Toronto
Study: 15122959
Drug: Voucher‐based reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Los Angeles
Study: 12324553
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a plus ribavirin (180 microg once weekly + daily ribavirin 1000 or 1200 mg)
Study: 12324553
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b plus ribavirin (3 million units thrice weekly + daily ribavirin)
Study: 12324553
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a alone (weekly peginterferon alfa‐2a + daily placebo)
Study: 9665239
Drug: DHE-PDT (4.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE-PDT (4.25 mg/kg)
Study: 9665239
Drug: DHE-PDT (3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE-PDT (3.25 mg/kg)
Study: 8607303
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied 10 to 120 minutes before heel-lancing
Study: 2590615
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg 'biphasic' nifedipine taken 12 hourly for 10 days
Study: 28902084
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy (4 courses for LR, 6 courses for IR and HR) followed by restricted radiotherapy (RT) if partial remission. Low-dose involved field radiotherapy: 21 Gy plus 14 Gy boost for residual disease.
Study: 28902084
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy (6 courses) followed by 21 Gy involved field radiotherapy for HR patients achieving CR.
Study: 23873545
Drug: Infected group
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infected group (challenged with 10(5) ELD50/0.1 mL of infectious bronchitis virus)
Study: 21318563
Drug: Nicotine Cannon
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Cannon (NC) and mini-lozenge
Study: 19703383
Drug: Psycho-educational, coping-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational, coping-oriented therapy programme (PKB)
Study: 17867915
Drug: Enoxaparin (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (novel dosing for elderly patients)
Study: 11701711
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for 6 days
Study: 11701711
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment for 6 days
Study: 11701711
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment in GHD patients
Study: 11701711
Drug: Octreotide or
Normalized name: octreotide Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide or pegvisomant treatment in acromegalic patients for 3 months
Study: 9219043
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once a day) plus Pindolol (2.5 mg three times a day)
Study: 9219043
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once a day) plus Placebo
Study: 8279647
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 6 mg/kg one time or 1 mg/kg, then 6 mg/kg four days later
Study: 8279647
Drug: Single-dose DEC
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose DEC
Study: 29779816
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (6 capsules daily, each containing 180 mg EPA and 120 mg DHA)
Study: 29779816
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 capsules daily)
Study: 22362836
Drug: Videoconferencing (VC)
Normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing (VC) administration of RUDAS
Study: 22362836
Drug: Face-to-face (FTF)
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face (FTF) administration of RUDAS
Study: 7758177
Drug: TPA 100
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA 100 mg i.v. over 3 hours
Study: 43966
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, oral application)
Study: 43966
Drug: Carazolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carazolol (5 mg)
Study: 23511704
Drug: Isoflavones (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (100-200 mg daily)
Study: 23511704
Drug: Twice-daily to
Normalized name: ClindaMax 1 % Twice-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily to thrice-daily dosing frequency of isoflavones
Study: 9865671
Drug: Omacor (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (4 g/day for 4 months)
Study: 3219226
Drug: Immunohistochemical assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical assay for estrogen receptor (ER) status in primary tumors and metastases
Study: 24918629
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume with PEEP (6 mL/kg tidal volume, 5 cm H2O PEEP)